$227 Million is the total value of GREAT POINT PARTNERS LLC's 35 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VNDA | New | VANDA PHARMACEUTICALS INC | $12,914,000 | – | 1,388,599 | +100.0% | 5.68% | – |
| VSAR | New | VERSARTIS INC | $7,072,000 | – | 385,000 | +100.0% | 3.11% | – |
| SCMP | New | SUCAMPO PHARMACEUTICALS INCcl a | $7,002,000 | – | 450,000 | +100.0% | 3.08% | – |
| STML | New | STEMLINE THERAPEUTICS INC | $6,877,000 | – | 475,200 | +100.0% | 3.03% | – |
| ASND | New | ASCENDIS PHARMA A S | $5,896,000 | – | 339,863 | +100.0% | 2.60% | – |
| ADHD | New | ALCOBRA LTD | $5,539,000 | – | 983,786 | +100.0% | 2.44% | – |
| DYAX | New | DYAX CORP | $3,953,000 | – | 235,950 | +100.0% | 1.74% | – |
| HRTX | New | HERON THERAPEUTICS INC | $3,929,000 | – | 270,000 | +100.0% | 1.73% | – |
| AMPE | New | AMPIO PHARMACEUTICALS INCput | $3,174,000 | – | 421,500 | +100.0% | 1.40% | – |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $3,062,000 | – | 100,000 | +100.0% | 1.35% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $2,545,000 | – | 1,038,652 | +100.0% | 1.12% | – |
| ATHX | New | ATHERSYS INCcall | $2,391,000 | – | 830,200 | +100.0% | 1.05% | – |
| MELA | New | MELA SCIENCES INC | $1,464,000 | – | 569,591 | +100.0% | 0.64% | – |
| BVX | New | BOVIE MEDICAL CORP | $1,147,000 | – | 480,000 | +100.0% | 0.50% | – |
| ATHX | New | ATHERSYS INCput | $288,000 | – | 100,000 | +100.0% | 0.13% | – |
| OSIR | New | OSIRIS THERAPEUTICS INC NEW | $214,000 | – | 12,165 | +100.0% | 0.09% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.